Thiogenesis Therapeutics Corp. (TTI)
TSXV
Closed
Oct 15, 2026
Day's Range
0.510052 wk Range
0.4400Overview - TTI - Thiogenesis Therapeutics Corp.
Key Statistics
Valuation
Enterprise Value
27.71M
P/E (Trailing)
-3.39
PEG Ratio
0.13
Price / Book
5.20
EV / EBITDA
-3.78
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-87.21%
Return on Equity
-181.52%
Ownership
Shares Outstanding
69.97M
Float
55.42M
Held by Insiders
14.16%
Held by Institutions
0.00%
Price stats
Beta
0.60
50-Day Avg
0.5204
200-Day Avg
0.5495
Market Cap - TTI - Thiogenesis Therapeutics Corp.
Peers - TTI - Thiogenesis Therapeutics Corp.
Peer Comparison
Compared with companies in Biotechnology listed on TSXV.
- TTITSXVThiogenesis Therapeutics Corp.35.68MMarket Cap-33.33%52-week change-3.40P/E (Trailing)0.00%Profit Margin
- ARCHTSXVArch Biopartners Inc.57.74MMarket Cap-4.71%52-week change-35.42P/E (Trailing)0.00%Profit Margin
- AURATSXVAuranova Resources Inc.18.88MMarket Cap-140.82%52-week change-1.46P/E (Trailing)0.00%Profit Margin
- ALTTSXVAlturas Minerals Corp.2.91MMarket Cap+50.00%52-week change—P/E (Trailing)0.00%Profit Margin
- BSTTSXVBessor Minerals Inc.625.71KMarket Cap-150.00%52-week change-2.00P/E (Trailing)0.00%Profit Margin
Profile Summary - TTI - Thiogenesis Therapeutics Corp.
About
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company developing next-generation sulfur-based therapeutics known as thiols, designed to treat inherited and acquired mitochondrial diseases. The company's lead candidate, TTI-0102, is a prodrug composed of cysteamine that addresses limitations of…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
